AUR-AFKF-TTM1-A-1-1-R-A742-41
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.530
- DNA_REPAIR+0.400
- MYC_TARGETS_V1+0.290
- ADIPOGENESIS+0.240
- E2F_TARGETS+0.240
- PROTEIN_SECRETION+0.230
- MYC_TARGETS_V2+0.220
- MTORC1_SIGNALING+0.200
- PEROXISOME+0.200
- FATTY_ACID_METABOLISM+0.180
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.450
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- TNFA_SIGNALING_VIA_NFKB-0.430
- INTERFERON_GAMMA_RESPONSE-0.400
- TGF_BETA_SIGNALING-0.390
- ALLOGRAFT_REJECTION-0.380
- IL6_JAK_STAT3_SIGNALING-0.380
- INTERFERON_ALPHA_RESPONSE-0.380
- ANGIOGENESIS-0.360
- APICAL_SURFACE-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8518448 | — | C | 0.910 |
| 2 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.904 |
| 3 | MNG87 | — | — | 0.903 |
| 4 | SRR12475110 | — | — | 0.901 |
| 5 | SRR1797243 | — | cohortSC | 0.896 |
| 6 | TCGA-A8-A06Z-01A-11R-A00Z-07 | — | B | 0.892 |
| 7 | C3L-00993 | — | cohortSQ1 | 0.890 |
| 8 | BSR_20_0054redo_S62 | — | B | 0.890 |
| 9 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.889 |
| 10 | TCGA-66-2756-01A-01R-0851-07 | — | cohortA3 | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.530 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.400 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.240 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.230 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.220 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PEROXISOME | 0.200 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.180 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.160 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.090 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.060 | Inavolisib | — uncovered |